Bedel Financial Consulting’s Relmada Therapeutics RLMD Stock Holding History

Bedel Financial Consulting’s Portfolio RLMD Stock Details RLMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$69.2K	Hold	10,000	–	–	0.01%	308
2026 Q1	$69.6K	Hold	10,000	–	–	0.01%	293
2025 Q4	$48.3K	Hold	10,000	–	–	0.01%	288
2025 Q3	$20.1K	Hold	10,000	–	–	﹤0.01%	285
2025 Q2	$6K	Hold	10,000	–	–	﹤0.01%	274
2025 Q1	$3.57K	Hold	10,000	–	–	﹤0.01%	261
2024 Q4	$3.8K	Hold	10,000	–	–	﹤0.01%	267
2024 Q3	$32.4K	Hold	10,000	–	–	﹤0.01%	255
2024 Q2	$30K	Hold	10,000	–	–	﹤0.01%	249
2024 Q1	$46.5K	Hold	10,000	–	–	0.01%	252
2023 Q4	$41.4K	Hold	10,000	–	–	0.01%	243
2023 Q3	$30K	Hold	10,000	–	–	0.01%	234
2023 Q2	$24.6K	Buy	+10,000	New	+$27.6K	0.01%	239

Other funds holding RLMD

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Squadron Capital Management Westmont, Illinois $322M AUM

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

SSC

Spruce Street Capital New York $510M AUM

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

JHC

Jones Hill Capital New York $470M AUM

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Bedel Financial Consulting's RLMD Position: Q2 2026 in Review

Bedel Financial Consulting held its Relmada Therapeutics (RLMD) position steady in Q2 2026 at 10,000 shares worth $69.2K. The position accounts for 0.01% of the portfolio, ranked #308.

Bedel Financial Consulting first reported a position in RLMD in Q2 2023 and has held it in 13 quarters since. The position peaked at $69.6K in Q1 2026. 126 funds tracked by Wall St. Rank hold RLMD as of Q2 2026.

Bedel Financial Consulting held 10,000 shares of Relmada Therapeutics worth $69.2K as of Q2 2026.
Bedel Financial Consulting left its Relmada Therapeutics share count unchanged in Q2 2026.
Relmada Therapeutics made up 0.01% of Bedel Financial Consulting's portfolio in Q2 2026, its #308 holding.
Bedel Financial Consulting first reported a position in Relmada Therapeutics in Q2 2023 and has held it in 13 quarters since.
Bedel Financial Consulting's Relmada Therapeutics position peaked at $69.6K in Q1 2026.
126 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2026.

Based on Bedel Financial Consulting's 13F filing for Q2 2026, filed 29 Jul 2026.